Catalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for Budoprutug (CD19 Antibody) in Systemic Lupus Erythematosus. The expected timing is based on the latest available company guidance and may change.
08/06/26:- China Ph1b/2a first patient dosed; global Ph1b safety and biomarker data expected Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.